PRECISION
PRECISION proved that an MRI first finds more dangerous cancers with fewer biopsies.
500 men; clinically significant cancer detected in 38% vs 26%; insignificant cancer 9% vs 22%; 28% avoided biopsy. Changed guidelines worldwide.
Setting
Biopsy-naive men with raised PSA: MRI-targeted biopsy (biopsy only if MRI positive) vs standard TRUS biopsy
Phase
Phase 3
Sponsor
UCL
Registry
Headline result
Clinically significant cancer 38% vs 26%.
Reported
2018
Enrolled
500
Replication
Confirmed by PRECISE, MRI-FIRST, and the Göteborg-2 screening trial.
In plain words
What these results mean for people, not percentages
Detection of clinically significant cancerprimaryother endpoint
- 38 vs 26 out of 100 reached this endpoint with MRI-targeted biopsy compared with Standard TRUS biopsy; 12 more per 100.
- Roughly one extra person helped for every 8 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- The p-value (0.005) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Biopsy-naive men with raised PSA: MRI-targeted biopsy (biopsy only if MRI positive) vs standard TRUS biopsy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
500 participants enrolled.
Detection of clinically significant cancerprimary
· p = 0.005
MRI-targeted biopsy38 of 100
n = 252
Standard TRUS biopsy26 of 100
n = 248
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Detection of clinically significant cancerprimary | MRI-targeted biopsy | 252 | 38% | — | 0.005 | link |
| Standard TRUS biopsy | 248 | 26% |
Replication
Confirmed by PRECISE, MRI-FIRST, and the Göteborg-2 screening trial.Pages like this
not linked directly; found by shared links- IdeaTest whether calling Gleason 6 'not cancer' changes what men choose
- IdeaModern autopsy studies to measure how much silent cancer people carry
- IdeaCertified decision aids required for every preference-sensitive cancer decision
- IdeaAn international body to rename indolent lesions so 'cancer' means something
- TermGleason score / Grade Group
- IdeaProstate active surveillance without scheduled biopsies: MRI and blood tests decide
- IdeaMRI-first prostate screening with genetic pre-selection
- TrialProtecT